Exercise Treatment With Standard Therapy for Metastatic Breast Cancer Read more about Exercise Treatment With Standard Therapy for Metastatic Breast Cancer
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System Read more about An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
A Research Study for Latina Women Undergoing Breast Cancer Treatment Read more about A Research Study for Latina Women Undergoing Breast Cancer Treatment
Study of DF1001 in Patients With Advanced Solid Tumors Read more about Study of DF1001 in Patients With Advanced Solid Tumors
A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation Read more about A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Read more about Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Read more about Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C Read more about COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer Read more about HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) Read more about A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)